药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2015年
3期
297-299
,共3页
陈美仪%罗俏瑜%冯池微%冯景霞
陳美儀%囉俏瑜%馮池微%馮景霞
진미의%라초유%풍지미%풍경하
阿托伐他汀%阿司匹林%联合用药
阿託伐他汀%阿司匹林%聯閤用藥
아탁벌타정%아사필림%연합용약
Atorvastatin%Aspirin%Combined use of medications
目的：对比阿托伐他汀联合阿司匹林与分别单用的治疗效果。方法：选取2012年9月~2014年10月我院收治的90例急性脑梗死患者，随机分为阿托伐他汀联合阿司匹林（P+A）治疗组30例；单用阿司匹林（A）治疗组30例；单用阿托伐他汀（P）治疗组30例。对比联合用药组与单用药组神经功能缺损程度及疗效、血脂、颈部血管超声的变化，并随访3个月。结果：治疗后治疗组的甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）低于两个单独用药组（P＜0.05），治疗组颈总动脉内径明显扩大，也优于两个单用药组；而神经功能缺损评分和高密度脂蛋白胆固醇（HDL-C）（P+A）治疗组要高于其余两组（P＜0.05）；（P+A）治疗组总有效率95.3%，高于P组（73.2%）和A组（74.6%），P＜0.05，3个月随访未见脑梗死复发。结论：阿托伐他汀联合阿司匹林对治疗脑梗死，有利于患者神经功能的恢复和预后的改善，对改善血脂各项指标有着积极的意义，对预防脑梗死的复发，相对于单独使用阿托伐他汀和阿司匹林有着明显的优势。
目的：對比阿託伐他汀聯閤阿司匹林與分彆單用的治療效果。方法：選取2012年9月~2014年10月我院收治的90例急性腦梗死患者，隨機分為阿託伐他汀聯閤阿司匹林（P+A）治療組30例；單用阿司匹林（A）治療組30例；單用阿託伐他汀（P）治療組30例。對比聯閤用藥組與單用藥組神經功能缺損程度及療效、血脂、頸部血管超聲的變化，併隨訪3箇月。結果：治療後治療組的甘油三酯（TG）、總膽固醇（TC）、低密度脂蛋白膽固醇（LDL-C）低于兩箇單獨用藥組（P＜0.05），治療組頸總動脈內徑明顯擴大，也優于兩箇單用藥組；而神經功能缺損評分和高密度脂蛋白膽固醇（HDL-C）（P+A）治療組要高于其餘兩組（P＜0.05）；（P+A）治療組總有效率95.3%，高于P組（73.2%）和A組（74.6%），P＜0.05，3箇月隨訪未見腦梗死複髮。結論：阿託伐他汀聯閤阿司匹林對治療腦梗死，有利于患者神經功能的恢複和預後的改善，對改善血脂各項指標有著積極的意義，對預防腦梗死的複髮，相對于單獨使用阿託伐他汀和阿司匹林有著明顯的優勢。
목적：대비아탁벌타정연합아사필림여분별단용적치료효과。방법：선취2012년9월~2014년10월아원수치적90례급성뇌경사환자，수궤분위아탁벌타정연합아사필림（P+A）치료조30례；단용아사필림（A）치료조30례；단용아탁벌타정（P）치료조30례。대비연합용약조여단용약조신경공능결손정도급료효、혈지、경부혈관초성적변화，병수방3개월。결과：치료후치료조적감유삼지（TG）、총담고순（TC）、저밀도지단백담고순（LDL-C）저우량개단독용약조（P＜0.05），치료조경총동맥내경명현확대，야우우량개단용약조；이신경공능결손평분화고밀도지단백담고순（HDL-C）（P+A）치료조요고우기여량조（P＜0.05）；（P+A）치료조총유효솔95.3%，고우P조（73.2%）화A조（74.6%），P＜0.05，3개월수방미견뇌경사복발。결론：아탁벌타정연합아사필림대치료뇌경사，유리우환자신경공능적회복화예후적개선，대개선혈지각항지표유착적겁적의의，대예방뇌경사적복발，상대우단독사용아탁벌타정화아사필림유착명현적우세。
Objective: To discuss the effects of atorvastatin combined with aspirin and single drug therapy. Methods: Ninety cases of acute cerebral infarction patients were collected in our hospital from September 2012 to October 2014, the patients were divided into three groups: Atorvastatin combined with Aspirin (P+A) group (30 cases), Aspirin (A) group (30 cases) and Atorvastatin (P) group (30 cases), neural function defects, therapeutic effects and changes of blood lipid and neck vascular ultrasound were followed up for 3 months. Results: After the treatment, improvement of triglyceride, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, carotid artery inradium and neural function defect score in the P+A group were significantly better than the other two single drug groups (P<0.05). The total effectiveness of the P+A treatment group was 95.3%, significantly higher than those of the P group (73.2%) and A group (74.6%) (P<0.05), there were no recurrence of cerebral infarction in 3 months of follow-up. Conclusion: Atorvastatin combined with aspirin in the treatment of cerebral infarction can improve the nerve function and prognosis, be positive to blood lipids and prevent the recurrence of cerebral infarction, it has obvious advantages over single use of atorvastatin or aspirin.
